Livzon Pharmaceutical Group (000513) Fair Value & Analysis
Healthcare · CN · Market cap 28.3B CNY
Fair value as of: Jun 25, 2026
From 26 valuation models · updated 6 days ago
Share price −6.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥28.80 – ¥44.48 · fair‑value band ¥56.77 – ¥94.61 · the ¥29.27 price screens below the ¥75.69 fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Livzon Pharmaceutical Group (000513) currently trades at ¥29.27, while our model-based Fair Value estimate is ¥75.69 — implying the stock looks roughly 158.6% undervalued today. We read business quality at 66/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Livzon Pharmaceutical Group generated revenue of 11.7B CNY at a net margin of 16.8%. Revenue declined 9.7% year over year. It earns a return on equity of 15.1%. The balance sheet holds a net cash position of 5.5B CNY. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neurological field; and shenqi fuzheng injection and anti-viral granules for the traditional Chinese medicine field. It also produces APIs and intermediates, such as mevastatin, acarbose, teicoplanin, gentamycin sulfate, phenylalanine, vancomycin hydrochloride, daptomycin, milbemycin oxime, and ceftriaxone sodium, as well as diagnostic reagents such as diagnostic kits for IgM antibody to mycoplasma pneumonia; diagnostic kits for human …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Livzon Pharmaceutical Group reported revenue of ¥11.9B in FY2025 versus ¥12.1B in FY2021, a compound −0.3%/yr. Reported net income was ¥2.0B in FY2025, compounding +3.3%/yr from FY2021.
Is 000513 fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| 1276 1276 | HK$57.85 | HK$29.84 | -48% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Livzon Pharmaceutical Group (000513) undervalued?
What is the fair value of 000513?
What is the quality score of 000513?
What is the revenue of Livzon Pharmaceutical Group (000513)?
What is the net profit margin of 000513?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.